Nimesulida Germed

Nimesulida Germed may be available in the countries listed below.

Ingredient matches for Nimesulida Germed

Nimesulide

Nimesulide is reported as an ingredient of Nimesulida Germed in the following countries:

• Portugal

International Drug Name Search

Valexime

Valexime may be available in the countries listed below.

Ingredient matches for Valexime

Ceftriaxone

Ceftriaxone disodium salt (a derivative of Ceftriaxone) is reported as an ingredient of Valexime in the following countries:

• Italy

International Drug Name Search

Colonmen

Colonmen may be available in the countries listed below.

Ingredient matches for Colonmen

Dilazep

Dilazep dihydrochloride (a derivative of Dilazep) is reported as an ingredient of Colonmen in the following countries:

• Japan

International Drug Name Search

Calcitonina

Calcitonina may be available in the countries listed below.

Ingredient matches for Calcitonina

Calcitonin

Calcitonina (DCIT) is known as Calcitonin in the US.

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Nifedipine-Stada

Nifedipine-Stada may be available in the countries listed below.

Ingredient matches for Nifedipine-Stada

Nifedipine

Nifedipine is reported as an ingredient of Nifedipine-Stada in the following countries:

• Luxembourg

International Drug Name Search

Algix

Algix may be available in the countries listed below.

Ingredient matches for Algix

Etoricoxib

Etoricoxib is reported as an ingredient of Algix in the following countries:

• Italy

International Drug Name Search

Nicholase

Nicholase may be available in the countries listed below.

Ingredient matches for Nicholase

Serrapeptase

Serrapeptase is reported as an ingredient of Nicholase in the following countries:

• Japan

International Drug Name Search

Demerol Syrup

Pronunciation: me-PER-i-deen
Generic Name: Meperidine
Brand Name: Demerol

Demerol Syrup is used for:

Short-term treatment of moderate to severe pain. It may also be used for other conditions as determined by your doctor.

Demerol Syrup is a narcotic analgesic. It works in the brain and nervous system to decrease pain.

Do NOT use Demerol Syrup if:

• you are allergic to any ingredient in Demerol Syrup


• you have severely slow or difficult breathing


• you have taken a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days


• you are taking ritonavir, sibutramine, or sodium oxybate (GHB)

Contact your doctor or health care provider right away if any of these apply to you.

Before using Demerol Syrup:

Some medical conditions may interact with Demerol Syrup. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have had an allergic reaction to any codeine- or morphine-related medicine (eg, hydrocodone, oxycodone, dihydrocodeine, hydromorphone)


• if you have a history of lung or breathing problems (eg, asthma, chronic obstructive pulmonary disease [COPD], cor pulmonale); low levels of oxygen or high levels of carbon dioxide in the blood; sickle cell anemia; adrenal gland problems (eg, Addison disease, pheochromocytoma); curvature of the spine (scoliosis); thyroid problems; low blood pressure; an enlarged prostate; urinary blockage or trouble urinating; lung, liver, or kidney problems; heart problems (eg, fast or irregular heartbeat); seizures; or stomach or bowels problems (eg, inflammatory bowel disease)


• if you have or have recently had any head injury, brain tumor or other growths, or increased pressure in the brain


• if you drink alcohol; are going through withdrawal from alcohol or other substances; or have a history of alcohol or substance abuse or dependence, mental or mood problems, or suicidal thoughts or attempts


• if you have severe diarrhea due to taking an antibiotic (pseudomembranous colitis), constipation, stomach pain, low blood volume, dehydration, drowsiness, or severe weakness, or have had recent surgery

Some MEDICINES MAY INTERACT with Demerol Syrup. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Mixed narcotic agonist/antagonists (eg, butorphanol, pentazocine), naltrexone, or rifamycins (eg, rifampin) because they may decrease Demerol Syrup's effectiveness


• Furazolidone or MAOIs (eg, phenelzine) because the risk of serious side effects, including coma, difficulty breathing, low blood pressure, seizures, and irregular heartbeat, may be increased


• Selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine) or sibutramine because the risk of side effects, including increased body temperature, mental or mood changes, muscle twitching, or severe drowsiness, may be increased


• Acyclovir, cimetidine, phenothiazines (eg, chlorpromazine), phenytoin, or ritonavir because they may increase the risk of Demerol Syrup's side effects


• Muscle relaxers (eg, cyclobenzaprine) or sodium oxybate (GHB) because their actions and the risk of their side effects may be increased by Demerol Syrup

This may not be a complete list of all interactions that may occur. Ask your health care provider if Demerol Syrup may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Demerol Syrup:

Use Demerol Syrup as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Demerol Syrup by mouth with or without food.


• Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.


• Tell your doctor if you still experience pain or if your pain gets worse while taking Demerol Syrup.


• If Demerol Syrup is no longer needed, dispose of the liquid by flushing it down the toilet.


• If you miss a dose of Demerol Syrup and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Demerol Syrup.

Important safety information:

• Demerol Syrup may cause drowsiness, dizziness, or light-headedness. These effects may be worse if you take it with alcohol or certain medicines. Use Demerol Syrup with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Demerol Syrup may cause dizziness, light-headedness, or fainting; alcohol, hot weather, exercise, or fever can increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.


• Check with your doctor before you drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Demerol Syrup; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Demerol Syrup may cause constipation. Talk with your doctor or pharmacist about using a stool softener or laxative to prevent constipation. It is also important to maintain a diet adequate in fiber, drink plenty or water, and exercise to prevent constipation. If you become constipated while taking Demerol Syrup, talk with your doctor or pharmacist.


• Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor. Prolonged use of Demerol Syrup may increase the risk of toxicity, including seizures.


• Do not suddenly stop taking Demerol Syrup without first checking with your doctor. If you have been taking Demerol Syrup for more than a few weeks and your doctor tells you to stop taking it, your dose may need to be gradually lowered as directed by your doctor to avoid side effects.


• Tell your doctor or dentist that you take Demerol Syrup before you receive any medical or dental care, emergency care, or surgery.


• Use Demerol Syrup with caution in the ELDERLY; they may be more sensitive to its effects.


• Use Demerol Syrup with extreme caution in CHILDREN; they may be more sensitive to its effects, especially slowed or difficult breathing.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Demerol Syrup while you are pregnant. Demerol Syrup is found in breast milk. Do not breast-feed while using Demerol Syrup.

When used for long periods of time or at high doses, Demerol Syrup may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Demerol Syrup stops working well. Do not take more than prescribed.

When used for long periods of time or at high doses, some people develop a need to continue taking Demerol Syrup. This is known as DEPENDENCE or addiction.

If you suddenly stop taking Demerol Syrup, you may experience WITHDRAWAL symptoms, including anxiety; appetite loss; backache; chills; diarrhea; enlarged pupils; fast heartbeat or breathing rate; increased tears; irritability; muscle or joint pain; nausea; restlessness; runny nose; severe or persistent dizziness; sleeplessness; stomach cramps; sweating; vomiting; weakness; and yawning.

Possible side effects of Demerol Syrup:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; dizziness; drowsiness; flushing; light-headedness; loss of appetite; nausea; sweating; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; confusion; difficulty urinating; fainting; fast, slow, or irregular heartbeat; hallucinations; mental or mood changes; numbness of an arm or a leg; seizure; severe or persistent constipation or stomach pain; severe or persistent dizziness or lightheadedness; slowed, shallow, or difficult breathing; sudden severe headache, nausea, or vomiting; tremor; uncontrolled muscle movements; vision changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Demerol side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include chest pain; cold and clammy skin; fainting; limp muscles; loss of consciousness; low body temperature; severe dizziness or light-headedness; severe drowsiness; seizures; slowed heartbeat; slowed, shallow, or difficult breathing; small pupils.

Proper storage of Demerol Syrup:

Store Demerol Syrup at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Demerol Syrup out of the reach of children and away from pets.

General information:

• If you have any questions about Demerol Syrup, please talk with your doctor, pharmacist, or other health care provider.


• Demerol Syrup is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Demerol Syrup. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Demerol resources

• Demerol Side Effects (in more detail)
• Demerol Use in Pregnancy & Breastfeeding
• Drug Images
• Demerol Drug Interactions
• Demerol Support Group
• 34 Reviews for Demerol - Add your own review/rating

Compare Demerol with other medications

• Light Sedation
• Pain

Isosorbidemononitraat PCH

Isosorbidemononitraat PCH may be available in the countries listed below.

Ingredient matches for Isosorbidemononitraat PCH

Isosorbide Mononitrate

Isosorbide Mononitrate is reported as an ingredient of Isosorbidemononitraat PCH in the following countries:

• Netherlands

International Drug Name Search

Amoxicilline / Acide Clavulanique RPG

Amoxicilline/Acide Clavulanique RPG may be available in the countries listed below.

Ingredient matches for Amoxicilline/Acide Clavulanique RPG

Amoxicillin

Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxicilline/Acide Clavulanique RPG in the following countries:

• France

Clavulanate

Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Amoxicilline/Acide Clavulanique RPG in the following countries:

• France

International Drug Name Search

Vagifem

Vagifem is a brand name of estradiol topical, approved by the FDA in the following formulation(s):

VAGIFEM (estradiol - tablet; vaginal)

• 
  Manufacturer: NOVO NORDISK INC
  
  Approval date: November 25, 2009
  
  Strength(s): 10MCG ^[RLD]

Has a generic version of Vagifem been approved?

No. There is currently no therapeutically equivalent version of Vagifem available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vagifem. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Hormone composition
  Patent 7,018,992
  Issued: March 28, 2006
  Inventor(s): Koch; Karen & Kvorning; Ingelise
  Assignee(s): Novo Nordisk A/S
  Twice weekly administration of an analog to a Vagifem tablet which only contains 10 μg of active material has a sufficient effect.
  
  Patent expiration dates:
  
  
  • September 17, 2022
    
    ✓ 
    Patent use: TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 25, 2012 - USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
  
  

See also...

• Vagifem local Consumer Information (Cerner Multum)
• Estradiol Cream Consumer Information (Wolters Kluwer)
• Estradiol topical Consumer Information (Cerner Multum)
• Estradiol vaginal local Consumer Information (Cerner Multum)

Clopidogrel AL

Clopidogrel AL may be available in the countries listed below.

Ingredient matches for Clopidogrel AL

Clopidogrel

Clopidogrel besilate (a derivative of Clopidogrel) is reported as an ingredient of Clopidogrel AL in the following countries:

• Germany

International Drug Name Search

Alphaxalone

Alphaxalone may be available in the countries listed below.

Ingredient matches for Alphaxalone

Alfaxalone

Alphaxalone (BAN) is also known as Alfaxalone (Rec.INN)

International Drug Name Search

Glossary

BAN	British Approved Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Melaxose

Melaxose may be available in the countries listed below.

Ingredient matches for Melaxose

Lactulose

Lactulose is reported as an ingredient of Melaxose in the following countries:

• France

Paraffin liquid

Paraffin liquid is reported as an ingredient of Melaxose in the following countries:

• France

International Drug Name Search

Romatidine

Romatidine may be available in the countries listed below.

Ingredient matches for Romatidine

Ranitidine

Ranitidine is reported as an ingredient of Romatidine in the following countries:

• Romania

International Drug Name Search

Arranon

In the US, Arranon (nelarabine systemic) is a member of the drug class antimetabolites and is used to treat Acute Lymphoblastic Leukemia and Lymphoma.

US matches:

• Arranon

Ingredient matches for Arranon

Nelarabine

Nelarabine is reported as an ingredient of Arranon in the following countries:

• United States

International Drug Name Search

Fosfomycine

Fosfomycine may be available in the countries listed below.

Ingredient matches for Fosfomycine

Fosfomycin

Fosfomycine (DCF) is known as Fosfomycin in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Pilocarpine Eye Drops

Pilocarpine Eye Drops may be available in the countries listed below.

Ingredient matches for Pilocarpine Eye Drops

Pilocarpine

Pilocarpine hydrochloride (a derivative of Pilocarpine) is reported as an ingredient of Pilocarpine Eye Drops in the following countries:

• Malta

International Drug Name Search

Conazol

Conazol may be available in the countries listed below.

Ingredient matches for Conazol

Ketoconazole

Ketoconazole is reported as an ingredient of Conazol in the following countries:

• Mexico

International Drug Name Search

Fluocim

Fluocim may be available in the countries listed below.

Ingredient matches for Fluocim

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluocim in the following countries:

• Romania


• Switzerland

International Drug Name Search

Micozol

Micozol may be available in the countries listed below.

Ingredient matches for Micozol

Clotrimazole

Clotrimazole is reported as an ingredient of Micozol in the following countries:

• Venezuela

International Drug Name Search

Tamoxifeno

Tamoxifeno may be available in the countries listed below.

Ingredient matches for Tamoxifeno

Tamoxifen

Tamoxifen is reported as an ingredient of Tamoxifeno in the following countries:

• Chile


• Peru

Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Tamoxifeno in the following countries:

• Chile


• Colombia

International Drug Name Search

Omniderm

Omniderm may be available in the countries listed below.

Ingredient matches for Omniderm

Fluocinolone

Fluocinolone Acetonide is reported as an ingredient of Omniderm in the following countries:

• Italy

International Drug Name Search

Difenidramina Cloridrato

Difenidramina Cloridrato may be available in the countries listed below.

Ingredient matches for Difenidramina Cloridrato

Diphenhydramine

Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Difenidramina Cloridrato in the following countries:

• Italy

International Drug Name Search

Hyanit

Hyanit may be available in the countries listed below.

Ingredient matches for Hyanit

Urea

Urea is reported as an ingredient of Hyanit in the following countries:

• Germany

International Drug Name Search

Zifin

Zifin may be available in the countries listed below.

Ingredient matches for Zifin

Azithromycin

Azithromycin is reported as an ingredient of Zifin in the following countries:

• Indonesia

International Drug Name Search

Propanta

Propanta may be available in the countries listed below.

Ingredient matches for Propanta

Pantoprazole

Pantoprazole is reported as an ingredient of Propanta in the following countries:

• Bangladesh

International Drug Name Search

Parkilyne

Parkilyne may be available in the countries listed below.

Ingredient matches for Parkilyne

Selegiline

Selegiline hydrochloride (a derivative of Selegiline) is reported as an ingredient of Parkilyne in the following countries:

• South Africa

International Drug Name Search

d-Camphor

d-Camphor may be available in the countries listed below.

Ingredient matches for d-Camphor

Camphor

d-Camphor (JAN) is known as Camphor in the US.

International Drug Name Search

Glossary

JAN	Japanese Accepted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Hansaplast Wärme-Creme

Hansaplast Wärme-Creme may be available in the countries listed below.

Ingredient matches for Hansaplast Wärme-Creme

Capsaicin

Capsaicin is reported as an ingredient of Hansaplast Wärme-Creme in the following countries:

• Austria

International Drug Name Search

Simvast

Simvast may be available in the countries listed below.

Ingredient matches for Simvast

Simvastatin

Simvastatin is reported as an ingredient of Simvast in the following countries:

• Dominican Republic


• Ecuador


• Oman

International Drug Name Search

Septocipro Otico

Septocipro Otico may be available in the countries listed below.

Ingredient matches for Septocipro Otico

Ciprofloxacin

Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Septocipro Otico in the following countries:

• Spain

International Drug Name Search

Calcet

In the US, Calcet (calcium/vitamin d systemic) is a member of the drug class vitamin and mineral combinations and is used to treat Dietary Supplementation and Osteoporosis.

US matches:

• Calcet

Ingredient matches for Calcet

Calcium Acetate

Calcium Acetate is reported as an ingredient of Calcet in the following countries:

• Germany

International Drug Name Search

DesOwen Cream Kit Cream

Pronunciation: DES-oh-nide
Generic Name: Desonide
Brand Name: DesOwen Cream Kit

DesOwen Cream Kit Cream is used for:

Relieving inflammation and itching caused by certain skin conditions.

DesOwen Cream Kit Cream is kit that contains a topical corticosteroid and a moisturizing lotion. The corticosteroid reduces skin inflammation. The moisturizing lotion helps to moisturize the skin.

Do NOT use DesOwen Cream Kit Cream if:

• you are allergic to any ingredient in DesOwen Cream Kit Cream

Contact your doctor or health care provider right away if any of these apply to you.

Before using DesOwen Cream Kit Cream:

Some medical conditions may interact with DesOwen Cream Kit Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a skin infection, thinning of the skin, tuberculosis (TB), measles, chickenpox, shingles, or a positive TB skin test, or have recently had a vaccination


• if you are taking an oral corticosteroid (eg, prednisone)

Some MEDICINES MAY INTERACT with DesOwen Cream Kit Cream. However, no specific interactions with DesOwen Cream Kit Cream are known at this time.

Ask your health care provider if DesOwen Cream Kit Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use DesOwen Cream Kit Cream:

Use DesOwen Cream Kit Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• To use the corticosteroid cream: Apply a small amount of medicine to the affected area(s) as directed by your doctor. Gently rub the medicine in until it is evenly distributed.


• Wash your hands right away after applying DesOwen Cream Kit Cream, unless your hands are part of the treated area.


• Do not cover the treated area(s) with bandages or other dressings unless advised to do so by your health care provider.


• To use the moisturizing lotion: Apply as often as needed to help prevent dry skin.


• If you miss a dose of DesOwen Cream Kit Cream, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use DesOwen Cream Kit Cream.

Important safety information:

• DesOwen Cream Kit Cream is for external use only. Do not get it in your eyes, nose, or mouth. If you get it in any of these areas, rinse right away with cool tap water.


• Do NOT use more than the recommended dose or use for longer than prescribed without checking with your doctor.


• If your symptoms do not improve within 2 weeks or if they get worse, check with your doctor.


• Do not apply DesOwen Cream Kit Cream to the groin or diaper area unless your doctor tells you otherwise. If DesOwen Cream Kit Cream is applied to the groin or diaper area, apply a very small amount and do not use tight-fitting undergarments or plastic pants.


• Contact your doctor if you have a cut or sore that does not heal.


• Check with your doctor before you have any vaccines while you are using DesOwen Cream Kit Cream.


• Do not apply DesOwen Cream Kit Cream over large areas of the body without first checking with your doctor.


• Do not use other medicines or products on your skin without first checking with your doctor.


• Overuse of topical products may worsen your condition.


• Do not use DesOwen Cream Kit Cream for other skin conditions at a later time.


• DesOwen Cream Kit Cream is a corticosteroid. Before you start any new medicine, check the label to see if it has a corticosteroid in it too. If it does or if you are not sure, check with your doctor or pharmacist.


• Tell your doctor or dentist that you use DesOwen Cream Kit Cream before you receive any medical or dental care, emergency care, or surgery.


• Serious side effects may occur if too much of DesOwen Cream Kit Cream is absorbed through the skin. This may be more likely to occur if you use DesOwen Cream Kit Cream over a large area of the body. It may also be more likely if you wrap or bandage the area after you apply DesOwen Cream Kit Cream. The risk is greater in children. Do not use more than the prescribed dose. Contact your doctor right away if you develop unusual weight gain (especially in the face), muscle weakness, increased thirst or urination, confusion, unusual drowsiness, severe or persistent headache, or vision changes. Discuss any questions or concerns with your doctor.


• DesOwen Cream Kit Cream should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.


• Corticosteroids may affect growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks if they use DesOwen Cream Kit Cream.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using DesOwen Cream Kit Cream while you are pregnant. It is not known if DesOwen Cream Kit Cream is found in breast milk after topical use. If you are or will be breast-feeding while you use DesOwen Cream Kit Cream, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of DesOwen Cream Kit Cream:

All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Dry skin; mild, temporary stinging or burning.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); acne-like rash; burning, cracking, irritation, or peeling not present before you began using DesOwen Cream Kit Cream; excessive hair growth; inflamed hair follicles; inflammation around the mouth; thinning, softening, or discoloration of the skin.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: DesOwen side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision or other vision changes; muscle weakness; severe or persistent headache; symptoms of high blood sugar (eg, increased thirst or urination, confusion, unusual drowsiness); unusual weight gain, especially in the face.

Proper storage of DesOwen Cream Kit Cream:

Store DesOwen Cream Kit Cream at room temperature, between 36 and 86 degrees F (2 and 30 degrees C). Store in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep DesOwen Cream Kit Cream out of the reach of children and away from pets.

General information:

• If you have any questions about DesOwen Cream Kit Cream, please talk with your doctor, pharmacist, or other health care provider.


• DesOwen Cream Kit Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about DesOwen Cream Kit Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More DesOwen Cream Kit resources

• DesOwen Cream Kit Side Effects (in more detail)
• DesOwen Cream Kit Use in Pregnancy & Breastfeeding
• DesOwen Cream Kit Drug Interactions
• DesOwen Cream Kit Support Group
• 5 Reviews for DesOwen - Add your own review/rating

Compare DesOwen Cream Kit with other medications

• Atopic Dermatitis
• Dermatitis
• Eczema
• Psoriasis

Gabapentina Alter

Gabapentina Alter may be available in the countries listed below.

Ingredient matches for Gabapentina Alter

Gabapentin

Gabapentin is reported as an ingredient of Gabapentina Alter in the following countries:

• Portugal


• Spain

International Drug Name Search

Stildem

Stildem may be available in the countries listed below.

Ingredient matches for Stildem

Zolpidem

Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Stildem in the following countries:

• Australia

International Drug Name Search

Ribastamin

Ribastamin may be available in the countries listed below.

Ingredient matches for Ribastamin

Risedronic Acid

Risedronic Acid monosodium (a derivative of Risedronic Acid) is reported as an ingredient of Ribastamin in the following countries:

• Argentina

International Drug Name Search

Omeprazole Sandoz i.v.

Omeprazole Sandoz i.v. may be available in the countries listed below.

Ingredient matches for Omeprazole Sandoz i.v.

Omeprazole

Omeprazole sodium salt (a derivative of Omeprazole) is reported as an ingredient of Omeprazole Sandoz i.v. in the following countries:

• Australia

International Drug Name Search

Parcekion

Parcekion may be available in the countries listed below.

Ingredient matches for Parcekion

Amezinium Metilsulfate

Amezinium Metilsulfate is reported as an ingredient of Parcekion in the following countries:

• Japan

International Drug Name Search

Cetapred

In the US, Cetapred (prednisolone/sulfacetamide sodium ophthalmic) is a member of the drug class ophthalmic steroids with anti-infectives and is used to treat Blepharitis, Conjunctivitis - Bacterial, Keratitis, Keratoconjunctivitis and Uveitis.

US matches:

• Cetapred

Ingredient matches for Cetapred

Prednisolone

Prednisolone 21-acetate (a derivative of Prednisolone) is reported as an ingredient of Cetapred in the following countries:

• Oman

Sulfacetamide Sodium

Sulfacetamide sodium salt (a derivative of Sulfacetamide) is reported as an ingredient of Cetapred in the following countries:

• Oman

International Drug Name Search

Venla

Venla may be available in the countries listed below.

Ingredient matches for Venla

Venlafaxine

Venlafaxine hydrochloride (a derivative of Venlafaxine) is reported as an ingredient of Venla in the following countries:

• Israel

International Drug Name Search

Merobact

Merobact may be available in the countries listed below.

Ingredient matches for Merobact

Meropenem

Meropenem trihydrate (a derivative of Meropenem) is reported as an ingredient of Merobact in the following countries:

• Greece

International Drug Name Search

Phenogel

Phenogel may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Phenogel

Phenylbutazone

Phenylbutazone is reported as an ingredient of Phenogel in the following countries:

• United Kingdom

International Drug Name Search

Addex-Magnesium

Addex-Magnesium may be available in the countries listed below.

Ingredient matches for Addex-Magnesium

Magnesium Sulfate

Magnesium Sulfate heptahydrate (a derivative of Magnesium Sulfate) is reported as an ingredient of Addex-Magnesium in the following countries:

• Norway


• Sweden

International Drug Name Search

Aphtasolon

Aphtasolon may be available in the countries listed below.

Ingredient matches for Aphtasolon

Dexamethasone

Dexamethasone is reported as an ingredient of Aphtasolon in the following countries:

• Japan


• Taiwan

International Drug Name Search

Lipidex

Lipidex may be available in the countries listed below.

Ingredient matches for Lipidex

Simvastatin

Simvastatin is reported as an ingredient of Lipidex in the following countries:

• South Africa

International Drug Name Search

Penicilline G

Penicilline G may be available in the countries listed below.

Ingredient matches for Penicilline G

Benzylpenicillin

Benzylpenicillin is reported as an ingredient of Penicilline G in the following countries:

• Tunisia

International Drug Name Search

Tazocilline

Tazocilline may be available in the countries listed below.

Ingredient matches for Tazocilline

Piperacillin

Piperacillin sodium salt (a derivative of Piperacillin) is reported as an ingredient of Tazocilline in the following countries:

• France


• Tunisia

Tazobactam

Tazobactam sodium salt (a derivative of Tazobactam) is reported as an ingredient of Tazocilline in the following countries:

• France


• Tunisia

International Drug Name Search

Butorphanol Tartrate

Ingredient matches for Butorphanol Tartrate

Butorphanol

Butorphanol Tartrate (BANM, USAN) is known as Butorphanol in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Aciclovir Bexal

Aciclovir Bexal may be available in the countries listed below.

Ingredient matches for Aciclovir Bexal

Acyclovir

Aciclovir is reported as an ingredient of Aciclovir Bexal in the following countries:

• Spain

International Drug Name Search

Zopiclone Merck

Zopiclone-Merck may be available in the countries listed below.

Ingredient matches for Zopiclone-Merck

Eszopiclone

Zopiclone is reported as an ingredient of Zopiclone-Merck in the following countries:

• France


• Luxembourg

International Drug Name Search

Arvind

Arvind may be available in the countries listed below.

Ingredient matches for Arvind

Lamotrigine

Lamotrigine is reported as an ingredient of Arvind in the following countries:

• Croatia (Hrvatska)


• Serbia

International Drug Name Search

Metoprolol Apotex

Metoprolol Apotex may be available in the countries listed below.

Ingredient matches for Metoprolol Apotex

Metoprolol

Metoprolol succinate (a derivative of Metoprolol) is reported as an ingredient of Metoprolol Apotex in the following countries:

• Netherlands

International Drug Name Search

Ticinan

Ticinan may be available in the countries listed below.

Ingredient matches for Ticinan

Morphine

Morphine hydrochloride (a derivative of Morphine) is reported as an ingredient of Ticinan in the following countries:

• Italy

International Drug Name Search

Tolon

Tolon may be available in the countries listed below.

Ingredient matches for Tolon

Fluorometholone

Fluorometholone is reported as an ingredient of Tolon in the following countries:

• Myanmar

International Drug Name Search

Doxepin AL

Doxepin AL may be available in the countries listed below.

Ingredient matches for Doxepin AL

Doxepin

Doxepin hydrochloride (a derivative of Doxepin) is reported as an ingredient of Doxepin AL in the following countries:

• Germany

International Drug Name Search

Oxytrol

Oxytrol is a brand name of oxybutynin, approved by the FDA in the following formulation(s):

OXYTROL (oxybutynin - film, extended release; transdermal)

• 
  Manufacturer: WATSON LABS (UTAH)
  
  Approval date: February 26, 2003
  
  Strength(s): 3.9MG/24HR ^[RLD]

Has a generic version of Oxytrol been approved?

No. There is currently no therapeutically equivalent version of Oxytrol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oxytrol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Triacetin as a penetration enhancer for transdermal delivery of a basic drug
  Patent 5,601,839
  Issued: February 11, 1997
  Inventor(s): Quan; Danyi & Deshpanday; Ninad A. & Venkateshwaran; Srinivasan & Ebert; Charles D.
  Assignee(s): TheraTech, Inc.
  A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of penetration enhancer consisting essentially of triacetin, and a polymer later preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.
  
  Patent expiration dates:
  
  
  • April 26, 2015
    
  
  



• 
  Triacetin as a penetration enhancer for transdermal delivery of a basic drug
  Patent 5,834,010
  Issued: November 10, 1998
  Inventor(s): Quan; Danyi & Deshpanday; Ninad A. & Venkateshwaran; Srinivasan & Ebert; Charles D.
  Assignee(s): Theratech, Inc.
  A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of a penetration enhancer consisting essentially of triacetin, and a polymer layer preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.
  
  Patent expiration dates:
  
  
  • April 26, 2015
    
  
  



• 
  Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
  Patent 6,743,441
  Issued: June 1, 2004
  Inventor(s): Steven W.; Sanders & Charles D.; Ebert
  Assignee(s): Watson Pharmaceuticals, Inc.
  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
  Patent 7,081,249
  Issued: July 25, 2006
  Inventor(s): Sanders; Steven W. & Ebert; Charles D.
  Assignee(s): Watson Laboratories, Inc.
  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
  Patent 7,081,250
  Issued: July 25, 2006
  Inventor(s): Sanders; Steven W. & Ebert; Charles D.
  Assignee(s): Watson Laboratories, Inc.
  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
  Patent 7,081,251
  Issued: July 25, 2006
  Inventor(s): Sanders; Steven W. & Ebert; Charles D.
  Assignee(s): Watson Laboratories, Inc.
  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
  Patent 7,081,252
  Issued: July 25, 2006
  Inventor(s): Sanders; Steven W. & Ebert; Charles D.
  Assignee(s): Watson Laboratories, Inc.
  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for transdermal oxybutynin therapy
  Patent 7,179,483
  Issued: February 20, 2007
  Inventor(s): Ebert; Charles D. & Sanders; Steven W.
  Assignee(s): Watson Pharmaceuticals, Inc.
  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Oxytrol Consumer Information (Drugs.com)
• Oxytrol System Consumer Information (Wolters Kluwer)
• Oxytrol transdermal Consumer Information (Cerner Multum)
• Oxytrol Advanced Consumer Information (Micromedex)
• Oxybutynin Consumer Information (Drugs.com)
• Oxybutynin Consumer Information (Wolters Kluwer)
• Oxybutynin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Oxybutynin Gel Consumer Information (Wolters Kluwer)
• Oxybutynin Syrup Consumer Information (Wolters Kluwer)
• Oxybutynin System Consumer Information (Wolters Kluwer)
• Oxybutynin Consumer Information (Cerner Multum)
• Oxybutynin topical Consumer Information (Cerner Multum)
• Oxybutynin transdermal Consumer Information (Cerner Multum)
• Oxybutynin Advanced Consumer Information (Micromedex)
• Oxybutynin Transdermal Advanced Consumer Information (Micromedex)
• Oxybutynin Chloride AHFS DI Monographs (ASHP)

Novocral

Novocral may be available in the countries listed below.

Ingredient matches for Novocral

Ceftazidime

Ceftazidime pentahydrate (a derivative of Ceftazidime) is reported as an ingredient of Novocral in the following countries:

• Greece

International Drug Name Search

Lotorin

Lotorin may be available in the countries listed below.

Ingredient matches for Lotorin

Minoxidil

Minoxidil is reported as an ingredient of Lotorin in the following countries:

• Greece

International Drug Name Search

Sulbutiamine

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A11DA02

CAS registry number (Chemical Abstracts Service)

0003286-46-2

Chemical Formula

C32-H46-N8-O6-S2

Molecular Weight

702

Therapeutic Category

Vitamin B₁

Chemical Name

Propanoic acid, 2-methyl-, dithiobis[3-[1-[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino] ethylidene]-3,1-propanediyl] ester

Foreign Names

• Sulbutiaminum (Latin)
• Sulbutiamin (German)
• Sulbutiamine (French)
• Sulbutiamina (Spanish)

Generic Names

• Bisibutiamine (OS: JAN)
• Sulbutiamine (OS: DCF)
• Bisibutiamin (IS)
• S 5007 (IS)

Brand Names

• Acralion
  Servier, Netherlands Antilles; Servier, Aruba; Servier, Barbados; Servier, Bermuda; Servier, Bahamas; Servier, Grenada; Servier, Guyana; Servier, Jamaica; Servier, Cayman Islands; Servier, Saint Lucia; Servier, Trinidad & Tobago; Servier, Saint Vincent & The Grenadines



• Arcalion
  Euroetika, Colombia; Grünenthal, Chile; Grünenthal, Peru; Serdia, India; Servier, United Arab Emirates; Servier, Bahrain; Servier, Brazil; Servier, Switzerland; Servier, Costa Rica; Servier, Dominican Republic; Servier, Egypt; Servier, Spain; Servier, France; Servier, Ghana; Servier, Guatemala; Servier, Guyana; Servier, Hong Kong; Servier, Honduras; Servier, Iraq; Servier, Jordan; Servier, Kuwait; Servier, Lebanon; Servier, Luxembourg; Servier, Malta; Servier, Mexico; Servier, Malaysia; Servier, Nigeria; Servier, Nicaragua; Servier, Oman; Servier, Panama; Servier, Philippines; Servier, Portugal; Servier, Qatar; Servier, Saudi Arabia; Servier, Sudan; Servier, Singapore; Servier, El Salvador; Servier, Syria; Servier, Thailand; Servier, Turkey; Servier, Venezuela; Servier, Vietnam; Servier, Yemen



• Arcatamin
  Danapha, Vietnam



• Arnion
  HG.Pharm, Vietnam



• Enerion
  Egis, Russian Federation; Servier, Romania



• Megastene
  Servier, Argentina



• Pymeacolion
  PMP, Vietnam



• Surmenalit
  Faes, Costa Rica; Faes, Dominican Republic; Faes, Spain; Faes, Guatemala; Faes, Honduras; Faes, Nicaragua; Faes, Panama; Faes, El Salvador

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Indomethacin Vida

Indomethacin Vida may be available in the countries listed below.

Ingredient matches for Indomethacin Vida

Indometacin

Indometacin is reported as an ingredient of Indomethacin Vida in the following countries:

• Hong Kong

International Drug Name Search

Oxybutynin System

Pronunciation: OX-i-BUE-ti-nin
Generic Name: Oxybutynin
Brand Name: Oxytrol

Oxybutynin System is used for:

Relieving symptoms of bladder problems (urinary urgency, frequency, or leakage; loss of bladder control; and painful urination) in certain patients. It may also be used for other conditions as determined by your doctor.

Oxybutynin System is an anticholinergic. It works by relaxing muscles in the bladder.

Do NOT use Oxybutynin System if:

• you are allergic to any ingredient in Oxybutynin System


• you have bladder blockage or are unable to urinate


• you have certain stomach or bowel problems (eg, blockage, decreased muscle movement)


• you have uncontrolled narrow-angle glaucoma


• you are taking a solid oral potassium product (eg, tablet)

Contact your doctor or health care provider right away if any of these apply to you.

Before using Oxybutynin System:

Some medical conditions may interact with Oxybutynin System. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have trouble urinating or have very poor health


• if you have a history of heart problems (eg, heart failure, fast or irregular heartbeat), high blood pressure, nervous system problems, liver or kidney problems, myasthenia gravis, an enlarged prostate, an overactive thyroid, esophagus problems (eg, reflux disease, inflammation, narrowing), stomach or bowel problems (eg, colitis, inflammation, constipation), or a hiatal hernia


• if you have a history of glaucoma or increased pressure in the eyes, or if you are at risk of glaucoma (eg, family history of glaucoma)

Some MEDICINES MAY INTERACT with Oxybutynin System. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Bisphosphonates (eg, alendronate) because the risk of irritation of the esophagus may be increased


• Other anticholinergic medicines (eg, scopolamine), azole antifungals (eg, ketoconazole), or macrolide antibiotics (eg, erythromycin) because they may increase the risk of Oxybutynin System's side effects


• Solid oral potassium products (eg, tablets) because the risk of stomach or bowel irritation may be increased by Oxybutynin System


• Phenothiazines (eg, chlorpromazine) because their effectiveness may be decreased by Oxybutynin System and they may increase the risk of Oxybutynin System's side effects

This may not be a complete list of all interactions that may occur. Ask your health care provider if Oxybutynin System may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Oxybutynin System:

Use Oxybutynin System as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Oxybutynin System. Talk to your pharmacist if you have questions about this information.


• Apply the patch to a clean, dry, smooth area of your skin on your stomach, hips, or buttocks. Apply it to an area under clothing to protect it from sunlight. Avoid applying it to your waistline because clothing may rub against the patch.


• Do NOT apply the patch to oily, damaged, or irritated skin. Avoid using oils, lotions, or powders near the application site because the patch may not stick to your skin.


• To use Oxybutynin System, open the pouch and remove the patch. Apply it right away. Carefully remove the first protective liner and place the patch firmly onto your skin. Do not touch the adhesive side of the patch. Bend the patch in half and gently roll the remaining part onto your skin. The second protective liner should come off of the patch. Gently apply firm pressure over the patch to be sure it stays in place.


• When it is time to apply a new patch, remove the old patch carefully. Fold the patch in half with the sticky sides together. Discard the patch out of the reach of children and pets because it may still contain medicine.


• Use a different skin site each time you apply a new patch. Do not reuse the same site within 7 days.


• Use Oxybutynin System on a regular schedule to get the most benefit from it. Using Oxybutynin System at the same time each day will help you remember to use it.


• Continue to use Oxybutynin System even if you feel well. Do not miss any doses.


• If the patch comes off, press it back in place and continue to follow your regular application schedule. If it does not stay on, throw it away and put a new patch on in a different area. Continue to follow your regular application schedule.


• If you forget to change the patch on the correct day, remove the old patch and apply a new patch to a different application site as soon as you remember. Continue to follow your regular application schedule. Do not use 2 patches at once.

Ask your health care provider any questions you may have about how to use Oxybutynin System.

Important safety information:

• Oxybutynin System may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Oxybutynin System with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Check with your doctor before you drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Oxybutynin System; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Oxybutynin System may cause decreased sweating. Do not become overheated in hot weather or while you are being active; heatstroke may occur. Contact your doctor if you have been exposed to high temperatures and you develop fever; flushing; hot, dry skin; severe or persistent headache; dizziness; sudden fatigue; fast heartbeat; seizures; or fainting.


• Oxybutynin System may cause dry mouth. To help relieve dry mouth, suck on sugarless hard candy or ice chips, chew sugarless gum, drink water, or use a saliva substitute. Ask your doctor or pharmacist if you have any questions.


• A serious side effect called angioedema has been reported with the use of oral dosage forms of Oxybutynin System (eg, tablets). Contact your doctor at once if you develop swelling of the hands, face, lips, eyes, throat, or tongue; difficulty swallowing or breathing; or hoarseness.


• Using Oxybutynin System while bathing, swimming, showering, or exercising will not change the way it works. However, avoid rubbing the patch area during these activities.


• Always remove the patch carefully and slowly to avoid damage to your skin. If there is adhesive left on your skin, gently wash the area with warm, soapy water. You may also use baby oil or a medical adhesive removal pad if needed. Do not use alcohol or nail polish remover because these may irritate the skin.


• After removing the patch, there may be minor redness of your skin. It should disappear after several hours. Tell your doctor if the irritation or redness becomes worse or if it does not go away.


• Use Oxybutynin System with caution in the ELDERLY; they may be more sensitive to its effects.


• Oxybutynin System should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: It is not known if Oxybutynin System can cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Oxybutynin System while you are pregnant. It is not known if Oxybutynin System is found in breast milk. If you are or will be breast-feeding while you use Oxybutynin System, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Oxybutynin System:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Blurred vision; constipation; diarrhea; dizziness; drowsiness; dry eyes, nose, skin, or mouth; headache; indigestion; nausea; minor redness, itching, or irritation at patch application site; stomach pain.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty swallowing or breathing; tightness in the chest; swelling of the mouth, face, lips, throat, or tongue; unusual hoarseness); confusion; difficult or painful urination; fast or irregular heartbeat; fever; hallucinations; mental or mood changes (eg, agitation); pain, burning, blistering, or oozing at the application site; seizures; swelling of the hands, ankles, or feet; vision problems.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Oxybutynin side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include coma; delirium; fever; flushing; hallucinations; inability to urinate; irregular heartbeat; paralysis; seizures; severe or persistent dizziness or headache; tremor; trouble breathing; vomiting.

Proper storage of Oxybutynin System:

Store Oxybutynin System at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store in original packaging until just before use. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Oxybutynin System out of the reach of children and away from pets.

General information:

• If you have any questions about Oxybutynin System, please talk with your doctor, pharmacist, or other health care provider.


• Oxybutynin System is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Oxybutynin System. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Oxybutynin resources

• Oxybutynin Side Effects (in more detail)
• Oxybutynin Use in Pregnancy & Breastfeeding
• Drug Images
• Oxybutynin Drug Interactions
• Oxybutynin Support Group
• 40 Reviews for Oxybutynin - Add your own review/rating

Compare Oxybutynin with other medications

• Dysuria
• Hyperhidrosis
• Overactive Bladder
• Prostatitis
• Urinary Incontinence

Isoptine

Isoptine may be available in the countries listed below.

Ingredient matches for Isoptine

Verapamil

Verapamil is reported as an ingredient of Isoptine in the following countries:

• Tunisia

Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Isoptine in the following countries:

• Belgium


• France

International Drug Name Search

Adenosina Biol

Adenosina Biol may be available in the countries listed below.

Ingredient matches for Adenosina Biol

Adenosine

Adenosine is reported as an ingredient of Adenosina Biol in the following countries:

• Argentina

International Drug Name Search

Micanol

In the US, Micanol is a member of the drug class topical antipsoriatics and is used to treat Psoriasis.

Ingredient matches for Micanol

Dithranol

Dithranol is reported as an ingredient of Micanol in the following countries:

• Australia


• Austria


• Bangladesh


• Germany


• Israel


• New Zealand


• Portugal


• United Kingdom

International Drug Name Search

Mukolen

Mukolen may be available in the countries listed below.

Ingredient matches for Mukolen

Eprazinone

Eprazinone dihydrochloride (a derivative of Eprazinone) is reported as an ingredient of Mukolen in the following countries:

• Bosnia & Herzegowina


• Croatia (Hrvatska)


• Slovenia

International Drug Name Search

Glucotab

Glucotab may be available in the countries listed below.

Ingredient matches for Glucotab

Glibenclamide

Glibenclamide is reported as an ingredient of Glucotab in the following countries:

• Bangladesh

International Drug Name Search